Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 13373 | 28.225 |
09:34 ET | 100 | 28.235 |
09:36 ET | 5428 | 28.27 |
09:38 ET | 879 | 28.255 |
09:39 ET | 2511 | 28.21 |
09:41 ET | 200 | 28.215 |
09:43 ET | 1045 | 28.215 |
09:45 ET | 4932 | 28.18 |
09:48 ET | 6476 | 28.19 |
09:50 ET | 1741 | 28.175 |
09:52 ET | 1027 | 28.156766 |
09:54 ET | 200 | 28.15 |
09:56 ET | 600 | 28.165 |
09:57 ET | 1458 | 28.15 |
09:59 ET | 5412 | 28.21 |
10:01 ET | 400 | 28.22 |
10:03 ET | 9242 | 28.27 |
10:06 ET | 2298 | 28.275 |
10:08 ET | 1873 | 28.33 |
10:10 ET | 612 | 28.335 |
10:12 ET | 3748 | 28.325 |
10:14 ET | 948 | 28.29 |
10:15 ET | 100 | 28.33 |
10:17 ET | 920 | 28.35 |
10:19 ET | 6546 | 28.32 |
10:21 ET | 100 | 28.315 |
10:24 ET | 5979 | 28.31 |
10:26 ET | 2037 | 28.31 |
10:28 ET | 1907 | 28.32 |
10:30 ET | 767 | 28.28 |
10:32 ET | 2700 | 28.265 |
10:33 ET | 1240 | 28.26 |
10:35 ET | 3721 | 28.27 |
10:37 ET | 3300 | 28.28 |
10:39 ET | 4461 | 28.29 |
10:42 ET | 700 | 28.295 |
10:44 ET | 100 | 28.295 |
10:46 ET | 8360 | 28.295 |
10:48 ET | 605 | 28.295 |
10:50 ET | 1600 | 28.315 |
10:51 ET | 2291 | 28.2847 |
10:53 ET | 100 | 28.28 |
10:55 ET | 1103 | 28.27 |
10:57 ET | 1400 | 28.26 |
11:00 ET | 5333 | 28.25 |
11:02 ET | 2993 | 28.2445 |
11:04 ET | 1500 | 28.205 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 16.6B | 18.8x | +1.83% |
Amneal Pharmaceuticals Inc | 2.7B | -13.2x | --- |
Endo Inc | 2.0B | 0.4x | --- |
Catalent Inc | 10.9B | -10.5x | --- |
Jazz Pharmaceuticals PLC | 6.7B | 19.2x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.6B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 2.98% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-13-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.8x |
Price/Sales (TTM) | 7.4 |
Price/Cash Flow (TTM) | 19.7x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.